The diagnosis of Alzheimer’s disease primarily depends on clinical symptoms, such as memory impairments and cognitive dysfunction, as well as neuroimaging findings (e.g., magnetic resonance imaging) and biomarkers, such as amyloid-beta and tau levels in cerebrospinal fluid. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.